Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose‐timing study

To assess the postprandial glucose‐lowering effect of the human amylin analog pramlintide when given with insulin lispro in subjects with type 2 diabetes, with an emphasis on the optimal dose timing relative to meals.

[1]  L. Bouter,et al.  Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study , 1999, Diabetologia.

[2]  J. Buse,et al.  Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy , 2002 .

[3]  C. Weyer,et al.  Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. , 2001, Current pharmaceutical design.

[4]  O. Kolterman,et al.  Pramlintide: A Human Amylin Analogue Reduced Postprandial Plasma Glucose, Insulin, and C‐peptide Concentrations in Patients with Type 2 Diabetes , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[5]  S. Del Prato.  In search of normoglycaemia in diabetes: controlling postprandial glucose , 2002, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[6]  J. Habener,et al.  The glucagon-like peptides. , 1999, Endocrine reviews.

[7]  W. Scherbaum.  The role of amylin in the physiology of glycemic control , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[8]  L. Want,et al.  Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. , 2002, Diabetes technology & therapeutics.

[9]  A. Zinsmeister,et al.  Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus , 2002, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[10]  C. Weyer,et al.  Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. , 2002, Diabetes technology & therapeutics.

[11]  Richard Hellman,et al.  The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus : The AACE System of Intensive Diabetes Self-Management — 2002 Update , 2002 .

[12]  S. Edelman,et al.  Pramlintide as an adjunct to insulin therapy , 2003, Current diabetes reports.

[13]  M. Riddle.  Evening Insulin Strategy , 1990, Diabetes Care.

[14]  C. Weyer,et al.  The Human Amylin Analog, Pramlintide, Reduces Postprandial Hyperglucagonemia in Patients with Type 2 Diabetes Mellitus , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[15]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[16]  D. Reed,et al.  Postchallenge Glucose Concentration and Coronary Heart Disease in Men of Japanese Ancestry: Honolulu Heart Program , 1987, Diabetes.

[17]  R. Rizza,et al.  Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. , 2000, The Journal of clinical endocrinology and metabolism.

[18]  Standards of Medical Care for Patients With Diabetes Mellitus , 1991, Diabetes Care.

[19]  Dennis D. Kim,et al.  Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. , 2002, Current drug targets. Immune, endocrine and metabolic disorders.

[20]  D. Roulin,et al.  Effects of regular insulin or insulin LISPRO on glucose metabolism after an oral glucose load in patients with type 2 diabetes mellitus. , 1998, Diabetes & metabolism.

[21]  D. Bruttomesso,et al.  Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. , 1999, Diabetes.

[22]  1999 European Diabetes Policy Group.  A desktop guide to Type 2 diabetes mellitus , 1999 .

[23]  S. Schwartz,et al.  Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM , 1996, Diabetologia.

[24]  O. Schmitz,et al.  Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus , 2001, Expert opinion on investigational drugs.

[25]  R. Unger.  Glucagon physiology and pathophysiology. , 1971, The New England journal of medicine.